Over the past 12 months, 9 insiders at Tarsus Pharmaceuticals, Inc. filed 46 open-market SEC Form 4 transactions on TARS: 0 purchases worth $0 and 46 sales worth $16.2M. Insiders have been net sellers over this period. The most recent filing was on Jun 17, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 17, 26 | Bobak R. AzamianPresident/CEO and Board Chair | SELL | 5.4K | $61.81 | $335K |
| Jun 16, 26 | Jeffrey S FarrowSee Remarks | SELL | 14.4K | $60.95 | $877K |
| Jun 15, 26 | Katherine Goodrich | SELL | 3.0K | $62.08 | $183K |
| Mar 20, 26 | Seshadri NeervannanChief Operating Officer | SELL | 3.0K | $66.75 | $200K |
| Mar 19, 26 | Bobak R. AzamianPresident/CEO and Board Chair | SELL | 12.0K | $67.00 | $802K |
| Mar 19, 26 | Jeffrey S FarrowSee Remarks | SELL | 2.2K | $67.00 | $146K |
| Mar 19, 26 | Elizabeth Yeu LinChief Medical Officer | SELL | 390 | $67.00 | $26K |
| Mar 19, 26 | Aziz MottiwalaChief Commercial Officer | SELL | 4.4K | $67.00 | $297K |
| Mar 19, 26 | Seshadri NeervannanChief Operating Officer | SELL | 4.6K | $67.00 | $307K |
| Mar 19, 26 | Bryan WahlGeneral Counsel | SELL | 4.2K | $67.00 | $283K |
| Mar 19, 26 | Dianne C. WhitfieldChief Human Resources Officer | SELL | 4.2K | $67.00 | $280K |
| Mar 18, 26 | Bobak R. AzamianPresident/CEO and Board Chair | SELL | 11.7K | $68.71 | $802K |
| Mar 18, 26 | Jeffrey S FarrowSee Remarks | SELL | 2.1K | $68.71 | $147K |
| Mar 18, 26 | Elizabeth Yeu LinChief Medical Officer | SELL | 379 | $68.71 | $26K |
| Mar 18, 26 | Aziz MottiwalaChief Commercial Officer | SELL | 4.3K | $68.71 | $298K |
| Mar 18, 26 | Seshadri NeervannanChief Operating Officer | SELL | 3.6K | $68.71 | $248K |
| Mar 18, 26 | Bryan WahlGeneral Counsel | SELL | 4.1K | $68.71 | $283K |
| Mar 18, 26 | Dianne C. WhitfieldChief Human Resources Officer | SELL | 4.1K | $68.71 | $280K |
| Mar 17, 26 | Bobak R. AzamianPresident/CEO and Board Chair | SELL | 11.0K | $69.42 | $762K |
| Mar 17, 26 | Jeffrey S FarrowSee Remarks | SELL | 2.1K | $69.42 | $147K |
| Mar 17, 26 | Elizabeth Yeu LinChief Medical Officer | SELL | 375 | $69.42 | $26K |
| Mar 17, 26 | Aziz MottiwalaChief Commercial Officer | SELL | 4.3K | $69.42 | $298K |
| Mar 17, 26 | Seshadri NeervannanChief Operating Officer | SELL | 3.1K | $69.42 | $217K |
| Mar 17, 26 | Bryan WahlGeneral Counsel | SELL | 4.1K | $69.42 | $284K |
| Mar 17, 26 | Dianne C. WhitfieldChief Human Resources Officer | SELL | 4.0K | $69.42 | $280K |
| Mar 16, 26 | Link William J PhdDirector | SELL | 8.4K | $69.75 | $578K |
| Mar 4, 26 | Seshadri NeervannanChief Operating Officer | SELL | 8.4K | $76.67 | $641K |
| Jan 2, 26 | Dianne C. WhitfieldChief Human Resources Officer | SELL | 8.1K | $82.93 | $656K |
| Dec 24, 25 | Bobak R. AzamianPresident/CEO and Board Chair | SELL | 5.4K | $83.54 | $449K |
| Dec 16, 25 | Dianne C. WhitfieldChief Human Resources Officer | SELL | 7.4K | $80.10 | $593K |
| Dec 16, 25 | Elizabeth Yeu LinChief Medical Officer | SELL | 2.1K | $79.50 | $165K |
| Dec 15, 25 | Link William J PhdDirector | SELL | 6.3K | $82.39 | $516K |
| Sep 24, 25 | Bobak R. AzamianPresident/CEO and Board Chair | SELL | 6.0K | $55.37 | $332K |
| Sep 8, 25 | Link William J PhdDirector | SELL | 27.1K | $57.00 | $1.5M |
| Aug 11, 25 | Bobak R. AzamianPresident/CEO and Board Chair | SELL | 6.0K | $50.00 | $300K |
| Jun 17, 25 | Jeffrey S FarrowSee Remarks | SELL | 13.6K | $40.42 | $550K |
| Jun 16, 25 | Elizabeth Yeu LinChief Medical Officer | SELL | 1.0K | $41.08 | $41K |
| Jun 9, 25 | Aziz MottiwalaChief Commercial Officer | SELL | 17.5K | $43.76 | $766K |
| Mar 24, 25 | Bobak R. AzamianPresident/CEO and Board Chair | SELL | 6.0K | $50.00 | $300K |
| Mar 20, 25 | Bobak R. AzamianPresident/CEO and Board Chair | SELL | 8.5K | $50.11 | $428K |
| Mar 20, 25 | Jeffrey S FarrowSee Remarks | SELL | 1.2K | $50.11 | $59K |
| Mar 20, 25 | Aziz MottiwalaChief Commercial Officer | SELL | 3.4K | $50.11 | $169K |
| Mar 20, 25 | Seshadri NeervannanChief Operating Officer | SELL | 2.4K | $50.11 | $122K |
| Mar 20, 25 | Bryan WahlGeneral Counsel | SELL | 3.1K | $50.11 | $155K |
| Mar 20, 25 | Dianne C. WhitfieldChief Human Resources Officer | SELL | 2.1K | $50.11 | $107K |
| Mar 19, 25 | Bobak R. AzamianPresident/CEO and Board Chair | SELL | 8.6K | $47.40 | $405K |
| Mar 19, 25 | Jeffrey S FarrowSee Remarks | SELL | 1.3K | $47.40 | $59K |
| Mar 19, 25 | Aziz MottiwalaChief Commercial Officer | SELL | 3.6K | $47.40 | $169K |
| Mar 19, 25 | Seshadri NeervannanChief Operating Officer | SELL | 2.5K | $47.40 | $121K |
| Mar 19, 25 | Bryan WahlGeneral Counsel | SELL | 3.3K | $47.40 | $155K |
Over the past 12 months, insiders at Tarsus Pharmaceuticals, Inc. filed 0 open-market purchases worth $0 and 46 sales worth $16.2M on TARS, which makes them net sellers over the period. The most recent Form 4 was filed on Jun 17, 26.
9 different insiders at Tarsus Pharmaceuticals, Inc. filed open-market SEC Form 4 transactions on TARS over the last 12 months.
InsiderTape plots every TARS insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Tarsus Pharmaceuticals, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →